Ph3 GDC-9545+ Palbo +/- Letro HER2- BC
(BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER Read Moreabout Ph3 GDC-9545+ Palbo +/- Letro HER2- BC
Phase: III
PH3 Enobosarm AR+ER+HER2- Fulv
(V3002401) ARTEST - A Randomized Crossover Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining ≥ 40% Who Have Shown Previous Disease Progression onBeen Previously Treated With a Nonsteroidal Aromatase Inhibitor FulvestrantSERD and CDK 4/6 inhibitorAromatase Inhibitor Fulvestrant and CDK 4/6 inhibitor Read Moreabout PH3 Enobosarm AR+ER+HER2- Fulv
Phase: III
Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) Read Moreabout Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
Phase: I
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
Ph2 Basket Tucat+Tras ST HER2 Alt
A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019) Read Moreabout Ph2 Basket Tucat+Tras ST HER2 Alt
Phase: II
STAR Ph2 Trila Sacit Gove TNBC
A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213) Read Moreabout STAR Ph2 Trila Sacit Gove TNBC
Phase: II
Ph3 Gem Carbo BC Preserve 2
A Phase 3 Randomized Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) (G1T28-208) Read Moreabout Ph3 Gem Carbo BC Preserve 2
Phase: III
PH3 Tras Deru HER2- BC
A Phase 3 Randomized Multi-center Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) (D9670C00001) Read Moreabout PH3 Tras Deru HER2- BC
Phase: III
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784) Read Moreabout Ph3 GDC-9545 ER+ HER2- BC (lidERA)
Phase: III
Ph3 HER2+/ER+ BC
A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571) Read Moreabout Ph3 HER2+/ER+ BC
Phase: III
Ph3 HER2/neu BC (FLAMINGO-01)
A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01) Read Moreabout Ph3 HER2/neu BC (FLAMINGO-01)
Phase: III
Ph3 Sac Gov Pemb vs PC BC
A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173) Read Moreabout Ph3 Sac Gov Pemb vs PC BC
Phase: III
Ph3 Sac GOv vs PC BC
A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238) Read Moreabout Ph3 Sac GOv vs PC BC
Phase: III
Ph1a/1b LY3484356 Abem ER+ HER2-
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA) Read Moreabout Ph1a/1b LY3484356 Abem ER+ HER2-
Phase: I
Ph3 LY3484356 ER+ HER2- BC
EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC) Read Moreabout Ph3 LY3484356 ER+ HER2- BC
Phase: III
PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA
EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202) Read Moreabout PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA
Phase: II
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY Read Moreabout Ph3 Nira Her2- triple- BC ctDNA (ZEST)
Phase: III
Ph 1b2 LIV1A+Pembro 1L mTNBC
Single Arm Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer (SGNLVA-002) Read Moreabout Ph 1b2 LIV1A+Pembro 1L mTNBC
Phase: I/II
Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) Read Moreabout Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
Phase: I
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors
Phase: II
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
STAR Ph3 MRTX849 Cetux KRAS G12C CC
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010) Read Moreabout STAR Ph3 MRTX849 Cetux KRAS G12C CC
Phase: III
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors
Phase: II
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
Ph 3 Pemb v Plat Dbl dMMR Endo Carcinoma
A Phase 3 Randomized Open-label Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (MK-3475-C93/GOG-3064) Read Moreabout Ph 3 Pemb v Plat Dbl dMMR Endo Carcinoma
Phase: III
Ph1a/1b LY3484356 Abem ER+ HER2-
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA) Read Moreabout Ph1a/1b LY3484356 Abem ER+ HER2-
Phase: I
Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) Read Moreabout Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
Phase: I
STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC
A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01) Read Moreabout STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC
Phase: I
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
A Phase 1b/2 study of the safety, PK, PD and preliminary efficacy of the FLT3 inhibitor gilteritinib, in combination with the selective SYK inhibitor lanraplenib (KB-9876), in patients with FLT3-mutated relapsed or refractory AML
STAR: Zanu in Acala intolerant B-Cell
A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell
Phase: II
Ph1b/2 Siremadlin + Vene + Azac AML
A phase Ib/II open label dose confirmation proof of concept study of siremadlin in combination with venetoclax plus azacitidine in unfit adult AML participants who responded sub-optimally to first-line venetoclax plus azacitidine treatment and in participants with newly diagnosed unfit AML presenting with high-risk clinical features (CHDM201I12201) Read Moreabout Ph1b/2 Siremadlin + Vene + Azac AML
Phase: I/II
Ph3 Ascim vs PC TKI new dx Ph+ CML
A phase III multi-center open-label randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12301) Read Moreabout Ph3 Ascim vs PC TKI new dx Ph+ CML
Phase: III
A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogenic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)(VIALE-T)
Phase: III
STAR Ph3b ABL001 in CML-CP +/-T315i
An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04) Read Moreabout STAR Ph3b ABL001 in CML-CP +/-T315i
Phase: III/IV
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)
Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) Read Moreabout Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
Phase: I
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors
Phase: II
Ph2 Basket Tucat+Tras ST HER2 Alt
A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019) Read Moreabout Ph2 Basket Tucat+Tras ST HER2 Alt
Phase: II
Ph2 Bren Vedo + Pembro ST prior PD-1
A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1
Phase: II
STAR Ph2 MRTX849 Pembro NSCLC KRAS
A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007) Read Moreabout STAR Ph2 MRTX849 Pembro NSCLC KRAS
Phase: II
STAR Ph3 Ami Laz EGFR-mut NSCLC
A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002) Read Moreabout STAR Ph3 Ami Laz EGFR-mut NSCLC
Phase: III
PH3 Nira Pembro Stg 3/4 NSCLC
A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400) Read Moreabout PH3 Nira Pembro Stg 3/4 NSCLC
Phase: III
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Parcipants with Newly Diagnosed Untreated Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Phase: III
STAR PH3 EGFRm stage2/3b NSCLC
A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001) Read Moreabout STAR PH3 EGFRm stage2/3b NSCLC
Phase: III
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC
Phase: III
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX) Read Moreabout STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
Phase: III
Ph2 Tomivosertib+Anti-PD-L1 NSCLC
A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011) Read Moreabout Ph2 Tomivosertib+Anti-PD-L1 NSCLC
Phase: II
STAR PH3 JNJ-61186372 Peme EGFR NSCLC
A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001) Read Moreabout STAR PH3 JNJ-61186372 Peme EGFR NSCLC
Phase: III
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Phase: III
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.
Phase: II
EF-36/Keynote B36: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer
Phase: PLT
Ph2 Nap r/r NSCLC
NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER Read Moreabout Ph2 Nap r/r NSCLC
Phase: II
Ph3 SAR408701 vs Doce NSCLC CEACAM5+
Randomized Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic non-squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors (EFC15858) Read Moreabout Ph3 SAR408701 vs Doce NSCLC CEACAM5+
Phase: III
STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C
RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies Read Moreabout STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C
Phase: II
STAR BV in pts w/1L cHL or PTCL
(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy Read Moreabout STAR BV in pts w/1L cHL or PTCL
Phase: II
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302) Read Moreabout Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
Phase: I
STAR: Zanu in Acala intolerant B-Cell
A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell
Phase: II
Ph2 Lonca-R DLBCL
A Phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9/ ADCT-402-203) Read Moreabout Ph2 Lonca-R DLBCL
Phase: II
A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: II/III
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
Phase: III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
A Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)
Phase: II
Ph2 Sub Mosunetuzumab B-cell malig
AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389) Read Moreabout Ph2 Sub Mosunetuzumab B-cell malig
Phase: II
A Multicenter Phase 2, Open Label Study of Intratumoral Tavo Plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment (PISCES)
Phase: II
Ph2 Bren Vedo + Pembro ST prior PD-1
A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1
Phase: II
A Phase 3, Randomized ,Double-blind Study of Adjuvant Immunotherapy with Relalimab+Nivolumab versus Nivolumab after Complete Resection of Stage III-IV Melanoma
Phase: III
A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma
Phase: II
PVSRIPO with and without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
A Phase 1b Study of ABBV-744 Alone or in Combination with Ruxolitinib or Navitoclax in Subjects with Myelofibrosis (M20-247)
Phase: Ib
STAR Ph2 Selinexor vs PC MF
A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035) Read Moreabout STAR Ph2 Selinexor vs PC MF
Phase: II
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
STAR Ph3 Navi Ruxo Myelofibrosis
M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1) Read Moreabout STAR Ph3 Navi Ruxo Myelofibrosis
Phase: III
Ph1b TRK-950 Ovarian Peri & Fallopian
A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02) Read Moreabout Ph1b TRK-950 Ovarian Peri & Fallopian
Phase: I
Ph1b/2 XMT-1536 ST NaPi2b
A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048) Read Moreabout Ph1b/2 XMT-1536 ST NaPi2b
Phase: II
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
STAR Ph2 VS-6766 Fak-Inhib LGSOC
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052) Read Moreabout STAR Ph2 VS-6766 Fak-Inhib LGSOC
Phase: II
PH3 Alpe BYL719 Olap BRCA OC
EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301) Read Moreabout PH3 Alpe BYL719 Olap BRCA OC
Phase: III
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors
Phase: II
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301) Read Moreabout Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
Phase: III
PANOVA-3: 1L Gemcit + nab-pac pancreatic
PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27) Read Moreabout PANOVA-3: 1L Gemcit + nab-pac pancreatic
Phase: III
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors.
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial
A Phase 1, Multi-Center, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adult Patients with Advanced Solid Tumors
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors
Phase: II
A Phase 1-2 Dose-Escalation and Expansion Study ofST101 in Patients with Advanced Unresectable and Metastatic Solid Tumors
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
Ph2 Basket Tucat+Tras ST HER2 Alt
A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019) Read Moreabout Ph2 Basket Tucat+Tras ST HER2 Alt
Phase: II
Ph2 Bren Vedo + Pembro ST prior PD-1
A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1
Phase: II
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
A Phase I, First-in-human, Open-label, Dose escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454 alone and in combination with Ipilimumab and Nivolumab
A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients with Advanced Solid Tumors or Lymphoma
Phase: Phase I/II
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations
Phase: II
An Open Label, Multicenter, Long-Term Extension Study of Tislelizumab-Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies
Phase: III
An Open-Label Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of TAK-573 as a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced or Metastatic Solid Tumors”